HL-085

DRUG9 trials

Sponsors

Shanghai Kechow Pharma, Inc., Kechow Pharma, Inc.

Conditions

CRCMelanomaNeurofibromatosis 1NsclcPlexiform NeurofibromasSolid TumorSolid Tumor, Adult

Phase 1

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Shanghai Kechow Pharma, Inc.Solid Tumor

Start: 2018-07-01End: 2023-12-01Target: 45Updated: 2023-05-31

Study of HL-085 in NRAS Mutant Advanced Melanoma

CompletedNCT03973151

Shanghai Kechow Pharma, Inc.Melanoma

Start: 2017-09-01End: 2021-01-18Updated: 2023-05-31

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

TerminatedNCT03976050

Shanghai Kechow Pharma, Inc.Solid Tumor, Adult

Start: 2019-06-17End: 2020-11-12Updated: 2020-11-18

Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

TerminatedNCT03990077

Shanghai Kechow Pharma, Inc.Nsclc

Start: 2020-05-21End: 2021-07-20Updated: 2021-12-10

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

CompletedNCT04683354

Kechow Pharma, Inc.Solid Tumor, Adult

Start: 2020-12-23End: 2022-12-08Updated: 2023-02-13

Phase 2

HL-085 in NRAS-mutated Advanced Melanoma

CompletedNCT05217303

Shanghai Kechow Pharma, Inc.Melanoma

Start: 2020-11-02End: 2023-02-20Updated: 2023-05-31

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Shanghai Kechow Pharma, Inc.CRC

Start: 2022-02-24End: 2024-07-20Target: 186Updated: 2023-05-31

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Shanghai Kechow Pharma, Inc.Melanoma

Start: 2021-09-06End: 2024-12-31Target: 104Updated: 2023-05-31

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

RecruitingNCT05331105

Shanghai Kechow Pharma, Inc.Neurofibromatosis 1, Plexiform Neurofibromas

Start: 2021-10-18End: 2028-10-31Target: 70Updated: 2023-05-31

Related Papers

A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated <i>BRAF</i> <sup>V600E</sup> -mutant metastatic colorectal cancer.

Journal of Clinical Oncology2026-06-03

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study.

2024-06-123 citations

Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

Journal of Clinical Oncology2024-06-013 citations

A phase II study of tunlametinib in combination with vemurafenib in patients with BRAF V600-mutant advanced melanoma.

Journal of Clinical Oncology2024-06-012 citations

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

2024-03-1114 citations

Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

Journal of Clinical Oncology2023-06-016 citations

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.

2023-01-0412 citations